Shattuck Labs Key Executives
This section highlights Shattuck Labs's key executives, including their titles and compensation details.
Find Contacts at Shattuck Labs
(Showing 0 of )
Shattuck Labs Earnings
This section highlights Shattuck Labs's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q3 | 2023 | 2023-11-10 | N/A | N/A |
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
$0.80
Stock Price
$38.52M
Market Cap
44
Employees
Austin, TX
Location
Financial Statements
Access annual & quarterly financial statements for Shattuck Labs, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $5.72M | $1.66M | $652.00K | $30.02M | $9.93M |
| Cost of Revenue | $- | $4.04M | $3.38M | $1.38M | $37.48M |
| Gross Profit | $5.72M | $-2.38M | $-2.72M | $28.64M | $-27.55M |
| Gross Profit Ratio | 100.00% | -143.93% | -417.64% | 95.40% | -277.32% |
| Research and Development Expenses | $67.21M | $74.31M | $82.90M | $56.56M | $37.48M |
| General and Administrative Expenses | $19.08M | $19.30M | $21.08M | $18.72M | $9.38M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $19.08M | $19.30M | $21.08M | $18.72M | $9.38M |
| Other Expenses | $- | $- | $-208.00K | $-330.00K | $-221.00K |
| Operating Expenses | $86.29M | $93.61M | $103.98M | $75.29M | $46.87M |
| Cost and Expenses | $86.29M | $93.61M | $103.98M | $75.29M | $46.87M |
| Interest Income | $5.17M | $4.67M | $1.59M | $625.00K | $549.00K |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $4.04M | $3.38M | $1.38M | $618.00K |
| EBITDA | $-80.57M | $-87.61M | $-100.26M | $-43.89M | $-36.31M |
| EBITDA Ratio | -1408.27% | -5287.57% | -15376.69% | -146.21% | -365.54% |
| Operating Income | $-80.57M | $-91.96M | $-103.33M | $-45.27M | $-36.93M |
| Operating Income Ratio | -1408.27% | -5549.61% | -15848.01% | -150.81% | -371.76% |
| Total Other Income Expenses Net | $5.16M | $4.66M | $1.38M | $295.00K | $328.00K |
| Income Before Tax | $-75.41M | $-87.30M | $-101.94M | $-44.97M | $-36.60M |
| Income Before Tax Ratio | -1318.13% | -5268.44% | -15635.74% | -149.83% | -368.46% |
| Income Tax Expense | $- | $- | $-1.38M | $-625.00K | $-1.17M |
| Net Income | $-75.41M | $-87.30M | $-100.56M | $-44.35M | $-35.44M |
| Net Income Ratio | -1318.13% | -5268.44% | -15423.47% | -147.75% | -356.71% |
| EPS | $-1.49 | $-2.05 | $-2.37 | $-1.06 | $-0.85 |
| EPS Diluted | $-1.49 | $-2.05 | $-2.37 | $-1.06 | $-0.85 |
| Weighted Average Shares Outstanding | 50.76M | 42.60M | 42.38M | 42.03M | 41.77M |
| Weighted Average Shares Outstanding Diluted | 50.76M | 42.60M | 42.38M | 42.03M | 41.77M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $3.00M | $1.61M | $1.11M | $714.00K | $686.00K | $200.00K | $57.00K | $390.00K | $212.00K | $50.00K | $- | $30.08M | $1.90M | $-4.23M | $2.27M | $1.34M | $2.44M | $3.18M | $2.98M |
| Cost of Revenue | $- | $- | $19.24M | $974.00K | $981.00K | $1.02M | $1.12M | $1.10M | $1.09M | $18.86M | $738.00K | $537.00K | $443.00K | $15.14M | $14.88M | $10.34M | $9.79M | $11.80M | $7.75M | $8.14M |
| Gross Profit | $- | $3.00M | $-17.63M | $141.00K | $-267.00K | $-334.00K | $-917.00K | $-1.04M | $-697.00K | $-18.65M | $-688.00K | $-537.00K | $29.64M | $-13.24M | $-19.11M | $-8.07M | $-8.45M | $-9.37M | $-4.57M | $-5.16M |
| Gross Profit Ratio | 0.00% | 100.00% | -1095.71% | 12.65% | -37.39% | -48.69% | -458.50% | -1828.07% | -178.72% | -8797.17% | -1376.00% | - | 98.53% | -696.68% | 451.74% | -355.37% | -629.28% | -384.76% | -143.79% | -173.42% |
| Research and Development Expenses | $15.39M | $16.31M | $19.24M | $16.26M | $15.23M | $24.21M | $18.20M | $16.67M | $21.89M | $18.86M | $22.96M | $19.19M | $16.21M | $15.14M | $14.88M | $10.34M | $9.79M | $11.80M | $7.75M | $8.14M |
| General and Administrative Expenses | $4.25M | $4.60M | $5.33M | $4.89M | $4.44M | $5.07M | $4.74M | $5.05M | $4.78M | $6.58M | $4.75M | $4.98M | $4.62M | $4.34M | $5.40M | $4.36M | $3.57M | $2.47M | $1.75M | $1.60M |
| Selling and Marketing Expenses | $- | $- | $- | $-974.00K | $-981.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $4.25M | $4.60M | $5.33M | $3.92M | $3.46M | $5.07M | $4.74M | $5.05M | $4.78M | $6.58M | $4.75M | $4.98M | $4.62M | $4.34M | $5.40M | $4.36M | $3.57M | $2.47M | $1.75M | $1.60M |
| Other Expenses | $- | $- | $- | $1.54M | $-3.40M | $1.06M | $1.40M | $937.00K | $-43.00K | $594.00K | $287.00K | $-362.00K | $-77.00K | $-81.00K | $-86.00K | $-86.00K | $-77.00K | $-76.00K | $-26.00K | $-43.00K |
| Operating Expenses | $19.64M | $20.92M | $24.57M | $20.18M | $18.68M | $29.28M | $22.95M | $21.72M | $26.67M | $25.44M | $27.71M | $24.17M | $20.83M | $19.48M | $20.28M | $14.69M | $13.35M | $14.27M | $9.50M | $9.74M |
| Cost and Expenses | $19.64M | $20.92M | $24.57M | $21.16M | $19.66M | $29.28M | $22.95M | $21.72M | $26.67M | $25.44M | $27.71M | $24.17M | $20.83M | $19.48M | $20.28M | $14.69M | $13.35M | $14.27M | $9.50M | $9.74M |
| Interest Income | $- | $- | $- | $- | $1.27M | $- | $- | $- | $1.59M | $- | $- | $- | $- | $251.00K | $1.00M | $696.00K | $75.00K | $86.00K | $138.00K | $250.00K |
| Interest Expense | $- | $- | $- | $- | $937.00K | $- | $- | $- | $- | $- | $- | $362.00K | $1.32M | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $940.00K | $953.00K | $962.00K | $974.00K | $981.00K | $1.02M | $1.12M | $1.10M | $1.09M | $934.00K | $738.00K | $537.00K | $443.00K | $380.00K | $329.00K | $228.00K | $170.00K | $156.00K | $152.00K | $140.00K |
| EBITDA | $-18.70M | $-16.97M | $-22.00M | $-19.07M | $-17.67M | $-27.58M | $-21.72M | $-20.65M | $-25.27M | $-24.30M | $-27.00M | $-23.69M | $9.69M | $-17.20M | $-24.18M | $-12.20M | $-11.84M | $-11.68M | $-6.17M | $-6.62M |
| EBITDA Ratio | - | -566.13% | -1367.31% | -1710.31% | -2474.79% | -4020.12% | -10860.00% | -36222.81% | -6479.74% | -11459.91% | -53992.00% | - | 32.21% | -905.26% | 571.57% | -537.22% | -882.34% | -479.79% | -193.90% | -222.48% |
| Operating Income | $-19.64M | $-17.92M | $-22.96M | $-20.04M | $-18.95M | $-28.60M | $-22.75M | $-21.66M | $-26.28M | $-25.23M | $-27.66M | $-24.17M | $9.25M | $-17.58M | $-24.51M | $-12.42M | $-12.01M | $-11.84M | $-6.32M | $-6.76M |
| Operating Income Ratio | - | -597.93% | -1427.10% | -1797.67% | -2654.20% | -4168.80% | -11373.50% | -38001.75% | -6737.44% | -11900.47% | -55316.00% | - | 30.74% | -925.26% | 579.34% | -547.27% | -895.01% | -486.20% | -198.68% | -227.18% |
| Total Other Income Expenses Net | $962.00K | $1.25M | $1.41M | $1.54M | $1.26M | $1.06M | $1.40M | $937.00K | $865.00K | $594.00K | $287.00K | $-362.00K | $-1.40M | $170.00K | $914.00K | $610.00K | $-1.00K | $10.00K | $112.00K | $207.00K |
| Income Before Tax | $-18.68M | $-16.68M | $-21.55M | $-18.50M | $-17.69M | $-27.54M | $-21.35M | $-20.72M | $-25.41M | $-24.64M | $-27.37M | $-24.53M | $7.85M | $-17.41M | $-23.60M | $-11.81M | $-12.01M | $-11.83M | $-6.21M | $-6.55M |
| Income Before Tax Ratio | - | -556.39% | -1339.47% | -1659.55% | -2477.17% | -4014.72% | -10673.00% | -36357.89% | -6515.64% | -11620.28% | -54742.00% | - | 26.09% | -916.32% | 557.74% | -520.40% | -895.16% | -485.79% | -195.16% | -220.23% |
| Income Tax Expense | $- | $- | $- | $930.72K | $937.00K | $1.06M | $904.91K | $-937.00K | $-865.00K | $-934.00K | $-287.00K | $362.00K | $1.32M | $-251.00K | $-1.33M | $-924.00K | $-245.00K | $-242.00K | $-138.00K | $-250.00K |
| Net Income | $-18.68M | $-16.68M | $-21.55M | $-18.50M | $-17.69M | $-27.54M | $-21.35M | $-19.79M | $-24.55M | $-24.64M | $-27.08M | $-24.89M | $7.85M | $-17.41M | $-23.60M | $-11.81M | $-12.01M | $-11.83M | $-6.21M | $-6.55M |
| Net Income Ratio | - | -556.39% | -1339.47% | -1659.55% | -2477.17% | -4014.72% | -10673.00% | -34714.04% | -6293.85% | -11620.28% | -54168.00% | - | 26.09% | -916.32% | 557.74% | -520.40% | -895.16% | -485.79% | -195.16% | -220.23% |
| EPS | $-0.37 | $-0.33 | $-0.42 | $-0.37 | $-0.41 | $-0.65 | $-0.50 | $-0.47 | $-0.58 | $-0.58 | $-0.64 | $-0.59 | $0.19 | $-0.41 | $-0.56 | $-0.28 | $-0.31 | $-0.31 | $-0.16 | $-0.34 |
| EPS Diluted | $-0.37 | $-0.33 | $-0.42 | $-0.37 | $-0.41 | $-0.65 | $-0.50 | $-0.47 | $-0.58 | $-0.58 | $-0.64 | $-0.59 | $0.18 | $-0.41 | $-0.56 | $-0.28 | $-0.31 | $-0.31 | $-0.16 | $-0.34 |
| Weighted Average Shares Outstanding | 50.84M | 50.83M | 50.79M | 50.57M | 43.01M | 42.48M | 42.47M | 42.44M | 42.39M | 42.39M | 42.38M | 42.36M | 42.29M | 42.16M | 41.91M | 41.77M | 38.80M | 38.08M | 38.08M | 19.11M |
| Weighted Average Shares Outstanding Diluted | 50.84M | 50.83M | 50.79M | 50.57M | 43.01M | 42.48M | 42.47M | 42.44M | 42.39M | 42.39M | 42.38M | 42.36M | 44.73M | 42.16M | 41.91M | 41.77M | 38.80M | 38.08M | 38.08M | 19.11M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $57.39M | $125.63M | $47.38M | $92.27M | $157.90M |
| Short Term Investments | $15.60M | $5.00M | $113.90M | $176.54M | $177.55M |
| Cash and Short Term Investments | $72.99M | $130.62M | $161.28M | $268.80M | $335.45M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $6.23M | $12.60M | $23.30M | $38.92M | $20.38M |
| Total Current Assets | $79.22M | $143.22M | $184.58M | $288.27M | $345.64M |
| Property Plant Equipment Net | $9.81M | $13.80M | $17.67M | $9.94M | $3.00M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $2.02M | $2.54M | $3.07M | $381.00K | $349.00K |
| Total Non-Current Assets | $11.83M | $16.34M | $20.74M | $10.32M | $3.35M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $91.05M | $159.56M | $205.32M | $298.58M | $348.99M |
| Account Payables | $2.42M | $1.59M | $7.17M | $10.01M | $1.75M |
| Short Term Debt | $- | $796.00K | $701.00K | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $-701.00K | $- | $7.73M |
| Other Current Liabilities | $6.50M | $9.07M | $17.09M | $14.57M | $7.35M |
| Total Current Liabilities | $8.92M | $11.45M | $24.96M | $24.59M | $16.83M |
| Long Term Debt | $2.51M | $3.41M | $4.20M | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $21.31M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $2.21M | $987.00K |
| Total Non-Current Liabilities | $2.51M | $3.41M | $4.20M | $2.21M | $22.29M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $11.42M | $14.86M | $29.17M | $26.80M | $39.13M |
| Preferred Stock | $- | $- | $- | $- | $348.99M |
| Common Stock | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K |
| Retained Earnings | $-381.72M | $-306.31M | $-219.01M | $-117.07M | $-72.09M |
| Accumulated Other Comprehensive Income Loss | $2.00K | $4.00K | $-877.00K | $-560.00K | $-63.00K |
| Other Total Stockholders Equity | $461.34M | $451.01M | $396.04M | $389.41M | $382.01M |
| Total Stockholders Equity | $79.63M | $144.71M | $176.16M | $271.79M | $309.86M |
| Total Equity | $79.63M | $144.71M | $176.16M | $271.79M | $309.86M |
| Total Liabilities and Stockholders Equity | $91.05M | $159.56M | $205.32M | $298.58M | $348.99M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $91.05M | $159.56M | $205.32M | $298.58M | $348.99M |
| Total Investments | $15.60M | $5.00M | $113.90M | $176.54M | $177.55M |
| Total Debt | $2.51M | $4.20M | $4.20M | $- | $- |
| Net Debt | $-54.88M | $-121.42M | $-43.18M | $-92.27M | $-157.90M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $57.39M | $43.83M | $60.69M | $76.00M | $125.63M | $40.63M | $71.89M | $66.04M | $47.38M | $39.76M | $37.87M | $50.74M | $92.27M | $85.09M | $86.49M | $84.73M | $157.90M | $128.60M | $131.04M | $-39.09M |
| Short Term Investments | $15.60M | $46.23M | $44.65M | $38.63M | $5.00M | $60.44M | $45.28M | $69.45M | $113.90M | $145.36M | $176.37M | $188.48M | $176.54M | $205.12M | $218.30M | $236.44M | $177.55M | $6.34M | $16.49M | $78.17M |
| Cash and Short Term Investments | $72.99M | $90.06M | $105.34M | $114.63M | $130.62M | $101.07M | $117.17M | $135.50M | $161.28M | $185.11M | $214.24M | $239.22M | $268.80M | $290.21M | $304.80M | $321.18M | $335.45M | $134.94M | $147.53M | $39.09M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $6.23M | $- | $9.08M | $16.44M | $12.60M | $11.91M | $19.28M | $22.34M | $23.30M | $16.40M | $15.18M | $15.76M | $19.46M | $22.86M | $22.16M | $19.80M | $20.38M | $12.23M | $5.25M | $- |
| Total Current Assets | $79.22M | $98.74M | $114.42M | $131.08M | $143.22M | $112.99M | $136.45M | $157.84M | $184.58M | $201.52M | $229.42M | $254.99M | $288.27M | $301.64M | $315.88M | $331.08M | $345.64M | $142.25M | $152.78M | $39.09M |
| Property Plant Equipment Net | $9.81M | $10.83M | $11.89M | $12.83M | $13.80M | $14.80M | $16.02M | $16.89M | $17.67M | $18.24M | $18.76M | $12.27M | $9.94M | $8.65M | $7.57M | $5.41M | $3.00M | $2.52M | $2.57M | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $2.02M | $2.15M | $2.29M | $2.43M | $2.54M | $2.67M | $2.81M | $2.95M | $3.07M | $3.19M | $3.16M | $3.23M | $381.00K | $273.00K | $331.00K | $362.00K | $349.00K | $89.00K | $192.00K | $-39.09M |
| Total Non-Current Assets | $11.83M | $12.98M | $14.19M | $15.26M | $16.34M | $17.47M | $18.82M | $19.84M | $20.74M | $21.43M | $21.92M | $15.50M | $10.32M | $8.92M | $7.90M | $5.77M | $3.35M | $2.60M | $2.76M | $-39.09M |
| Other Assets | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $91.05M | $111.72M | $128.61M | $146.34M | $159.56M | $130.46M | $155.27M | $177.68M | $205.32M | $222.94M | $251.34M | $270.49M | $298.58M | $310.57M | $323.78M | $336.85M | $348.99M | $144.86M | $155.54M | $- |
| Account Payables | $2.42M | $2.93M | $2.82M | $2.15M | $1.59M | $2.02M | $2.01M | $5.13M | $7.17M | $3.04M | $5.67M | $2.59M | $10.01M | $3.25M | $1.01M | $3.00M | $1.75M | $1.35M | $1.10M | $- |
| Short Term Debt | $900.00K | $873.00K | $847.00K | $821.00K | $796.00K | $771.00K | $747.00K | $- | $701.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $3.00M | $4.61M | $- | $557.00K | $743.00K | $- | $-701.00K | $- | $-657.00K | $-607.00K | $- | $2.80M | $2.78M | $9.66M | $7.73M | $8.61M | $7.82M | $- |
| Other Current Liabilities | $5.60M | $8.60M | $8.36M | $6.75M | $9.07M | $10.71M | $9.49M | $10.88M | $17.09M | $16.10M | $18.57M | $14.22M | $14.57M | $13.78M | $11.33M | $5.25M | $7.35M | $6.52M | $13.39M | $- |
| Total Current Liabilities | $8.92M | $12.40M | $15.03M | $14.33M | $11.45M | $14.06M | $12.99M | $16.01M | $24.96M | $19.14M | $24.25M | $16.81M | $24.59M | $19.84M | $15.11M | $17.90M | $16.83M | $16.48M | $14.50M | $- |
| Long Term Debt | $2.51M | $2.74M | $2.97M | $3.19M | $3.41M | $3.62M | $3.82M | $4.01M | $4.20M | $4.39M | $4.57M | $4.74M | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $27.28M | $29.21M | $18.09M | $21.31M | $19.72M | $21.11M | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.21M | $2.29M | $2.37M | $2.20M | $987.00K | $167.01M | $21.97M | $- |
| Total Non-Current Liabilities | $2.51M | $2.74M | $2.97M | $3.19M | $3.41M | $3.62M | $3.82M | $4.01M | $4.20M | $4.39M | $4.57M | $4.74M | $2.21M | $29.57M | $31.58M | $20.29M | $22.29M | $186.74M | $21.97M | $- |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $11.42M | $15.14M | $18.00M | $17.52M | $14.86M | $17.67M | $16.81M | $20.02M | $29.17M | $23.52M | $28.81M | $21.55M | $26.80M | $49.40M | $46.69M | $38.19M | $39.13M | $203.22M | $36.46M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $117.06M | $- | $- | $- | $- | $49.06M | $- | $49.06M |
| Common Stock | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $1.00K | $3.00K | $- |
| Retained Earnings | $-381.72M | $-363.04M | $-346.37M | $-324.81M | $-306.31M | $-288.62M | $-261.08M | $-239.74M | $-219.01M | $-193.60M | $-168.97M | $-141.59M | $-117.07M | $-124.91M | $-107.50M | $-83.91M | $-72.09M | $-60.08M | $-48.25M | $- |
| Accumulated Other Comprehensive Income Loss | $2.00K | $52.00K | $-5.00K | $-14.00K | $4.00K | $7.00K | $-74.00K | $-339.00K | $-877.00K | $-1.33M | $-1.11M | $-527.00K | $-560.00K | $-1.83M | $-1.62M | $-660.00K | $-63.00K | $-10.00K | $18.00K | $-34.55M |
| Other Total Stockholders Equity | $461.34M | $459.56M | $456.98M | $453.64M | $451.01M | $401.39M | $399.61M | $397.72M | $396.04M | $394.35M | $392.60M | $391.06M | $389.41M | $387.90M | $386.21M | $383.22M | $382.01M | $188.48M | $167.31M | $- |
| Total Stockholders Equity | $79.63M | $96.58M | $110.62M | $128.81M | $144.71M | $112.78M | $138.46M | $157.65M | $176.16M | $199.42M | $222.53M | $248.94M | $271.79M | $261.17M | $277.09M | $298.66M | $309.86M | $-58.36M | $119.08M | $14.52M |
| Total Equity | $79.63M | $96.58M | $110.62M | $128.81M | $144.71M | $112.78M | $138.46M | $157.65M | $176.16M | $199.42M | $222.53M | $248.94M | $271.79M | $261.17M | $277.09M | $298.66M | $309.86M | $-58.36M | $119.08M | $14.52M |
| Total Liabilities and Stockholders Equity | $91.05M | $111.72M | $128.61M | $146.34M | $159.56M | $130.46M | $155.27M | $177.68M | $205.32M | $222.94M | $251.34M | $270.49M | $298.58M | $310.57M | $323.78M | $336.85M | $348.99M | $144.86M | $155.54M | $14.52M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $91.05M | $111.72M | $128.61M | $146.34M | $159.56M | $130.46M | $155.27M | $177.68M | $205.32M | $222.94M | $251.34M | $270.49M | $298.58M | $310.57M | $323.78M | $336.85M | $348.99M | $144.86M | $155.54M | $14.52M |
| Total Investments | $15.60M | $46.23M | $44.65M | $38.63M | $5.00M | $60.44M | $45.28M | $69.45M | $113.90M | $145.36M | $176.37M | $188.48M | $176.54M | $205.12M | $218.30M | $236.44M | $177.55M | $6.34M | $16.49M | $78.17M |
| Total Debt | $3.41M | $3.62M | $3.82M | $4.01M | $4.20M | $4.39M | $4.57M | $4.01M | $4.20M | $4.39M | $4.57M | $4.74M | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Debt | $-53.98M | $-40.21M | $-56.87M | $-71.99M | $-121.42M | $-36.25M | $-67.33M | $-62.03M | $-43.18M | $-35.37M | $-33.30M | $-46.01M | $-92.27M | $-85.09M | $-86.49M | $-84.73M | $-157.90M | $-128.60M | $-131.04M | $39.09M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-75.41M | $-87.30M | $-101.94M | $-44.97M | $-36.60M |
| Depreciation and Amortization | $3.83M | $4.04M | $3.07M | $1.38M | $618.00K |
| Deferred Income Tax | $- | $- | $- | $3.04M | $1.00K |
| Stock Based Compensation | $9.55M | $6.94M | $6.46M | $5.47M | $1.27M |
| Change in Working Capital | $3.02M | $-4.09M | $-4.46M | $-23.55M | $970.00K |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $832.00K | $-5.63M | $-2.84M | $7.87M | $-1.75M |
| Other Working Capital | $2.19M | $1.53M | $-1.62M | $-31.41M | $2.72M |
| Other Non Cash Items | $-1.50M | $-816.00K | $2.38M | $1.52M | $89.00K |
| Net Cash Provided by Operating Activities | $-60.52M | $-81.23M | $-94.50M | $-57.12M | $-33.66M |
| Investments in Property Plant and Equipment | $-59.00K | $-407.00K | $-11.61M | $-7.93M | $-727.00K |
| Acquisitions Net | $- | $- | $104.00K | $2.52M | $145.59M |
| Purchases of Investments | $-93.55M | $-79.73M | $-132.38M | $-204.09M | $-183.19M |
| Sales Maturities of Investments | $85.10M | $191.00M | $193.32M | $201.57M | $37.59M |
| Other Investing Activities | $- | $- | $61.05M | $-2.52M | $-145.59M |
| Net Cash Used for Investing Activities | $-8.51M | $110.86M | $49.44M | $-10.44M | $-146.32M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $-17.00K | $48.17M | $171.00K | $1.93M | $232.30M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $804.00K | $945.00K | $171.00K | $1.93M | $98.56M |
| Net Cash Used Provided by Financing Activities | $787.00K | $48.62M | $171.00K | $1.93M | $330.87M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-68.24M | $78.25M | $-44.89M | $-65.63M | $150.88M |
| Cash at End of Period | $57.39M | $125.63M | $47.38M | $92.27M | $157.90M |
| Cash at Beginning of Period | $125.63M | $47.38M | $92.27M | $157.90M | $7.01M |
| Operating Cash Flow | $-60.52M | $-81.23M | $-94.50M | $-57.12M | $-33.66M |
| Capital Expenditure | $-59.00K | $-407.00K | $-11.61M | $-7.93M | $-727.00K |
| Free Cash Flow | $-60.57M | $-81.64M | $-106.11M | $-65.04M | $-34.39M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-18.68M | $-16.68M | $-21.55M | $-18.50M | $-17.69M | $-27.54M | $-21.35M | $-20.72M | $-25.41M | $-24.64M | $-27.37M | $-24.53M | $7.85M | $-17.41M | $-23.60M | $-11.81M | $-12.01M | $-11.83M | $-6.21M | $-6.55M |
| Depreciation and Amortization | $940.00K | $953.00K | $962.00K | $974.00K | $981.00K | $1.02M | $1.03M | $1.01M | $1.00M | $934.00K | $662.00K | $472.00K | $443.00K | $380.00K | $329.00K | $228.00K | $170.00K | $156.00K | $152.00K | $140.00K |
| Deferred Income Tax | $- | $- | $- | $- | $638.00K | $-347.00K | $-291.00K | $- | $- | $- | $- | $- | $2.26M | $772.00K | $2.00K | $- | $23.00K | $36.00K | $-20.00K | $-38.00K |
| Stock Based Compensation | $1.85M | $2.56M | $2.67M | $2.48M | $1.64M | $1.76M | $1.85M | $1.68M | $1.69M | $1.72M | $1.53M | $1.51M | $1.22M | $1.34M | $1.73M | $1.18M | $637.00K | $312.00K | $143.00K | $174.00K |
| Change in Working Capital | $-1.25M | $-2.41M | $7.52M | $-836.00K | $-4.12M | $8.28M | $52.00K | $-8.31M | $-1.00M | $-6.65M | $7.97M | $-4.78M | $-30.70M | $2.00M | $7.03M | $-1.87M | $-2.94M | $-74.00K | $8.21M | $-4.23M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-508.00K | $115.00K | $319.00K | $906.00K | $-475.00K | $20.00K | $-2.98M | $-2.20M | $4.36M | $-2.67M | $3.22M | $-7.74M | $7.02M | $1.75M | $-2.14M | $1.24M | $-50.00K | $246.00K | $-497.00K | $-1.45M |
| Other Working Capital | $-740.00K | $-2.53M | $7.20M | $-1.74M | $-3.65M | $8.26M | $3.03M | $-6.11M | $-5.36M | $5.00K | $4.75M | $2.96M | $-37.73M | $250.00K | $9.18M | $-3.11M | $-2.89M | $-320.00K | $8.71M | $-2.78M |
| Other Non Cash Items | $-233.00K | $-486.00K | $-512.00K | $3.25M | $-870.00K | $92.00K | $90.00K | $-128.00K | $-123.00K | $79.00K | $891.00K | $1.05M | $221.00K | $-77.00K | $170.00K | $1.21M | $76.00K | $51.00K | $-92.00K | $54.00K |
| Net Cash Provided by Operating Activities | $-17.37M | $-16.07M | $-10.92M | $-16.16M | $-19.42M | $-16.73M | $-18.62M | $-26.46M | $-23.84M | $-28.06M | $-16.32M | $-26.28M | $-18.72M | $-12.99M | $-14.34M | $-11.07M | $-14.04M | $-11.35M | $2.19M | $-10.45M |
| Investments in Property Plant and Equipment | $- | $-42.00K | $-17.00K | $- | $-17.00K | $-19.00K | $-296.00K | $-75.00K | $-693.00K | $-750.00K | $-7.68M | $-2.49M | $-1.99M | $-964.00K | $-2.33M | $-2.64M | $-201.00K | $-99.00K | $-319.00K | $-108.00K |
| Acquisitions Net | $- | $- | $- | $- | $-55.87M | $- | $- | $- | $104.00K | $- | $- | $- | $-25.60M | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $-29.88M | $-25.40M | $-38.28M | $-79.73M | $- | $-14.81M | $- | $-132 | $- | $11.12M | $-12.89M | $-39.01M | $-47.80M | $-42.80M | $-74.48M | $-177.61M | $-2.84M | $- | $-2.74M |
| Sales Maturities of Investments | $31.00M | $29.10M | $20.00M | $5.00M | $135.60M | $-14.53M | $24.73M | $45.20M | $193 | $- | $- | $- | $66.60M | $60.00M | $59.98M | $15.00M | $6.33M | $12.93M | $8.80M | $9.54M |
| Other Investing Activities | $- | $- | $- | $-33.28M | $55.87M | $-14.53M | $24.73M | $45.20M | $32.05M | $30.68M | $11.12M | $-12.89M | $27.59M | $12.20M | $17.18M | $-59.49M | $-171.29M | $10.09M | $8.80M | $6.81M |
| Net Cash Used for Investing Activities | $31.00M | $-821.00K | $-5.41M | $-33.28M | $55.85M | $-14.55M | $24.43M | $45.12M | $31.46M | $29.93M | $3.43M | $-15.38M | $25.60M | $11.24M | $14.84M | $-62.13M | $-171.49M | $9.99M | $8.48M | $6.70M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $-1.32M | $1.05M | $253.00K | $48.58M | $21.00K | $33.00K | $- | $171.00K | $- | $10.00K | $134.00K | $1.93M | $352.00K | $1.26M | $31.00K | $83.00M | $- | $- | $- |
| Common Stock Repurchased | $- | $454.00K | $-17.00K | $-437.00K | $-14.00K | $- | $- | $-39.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-6.00K | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-72.00K | $23.00K | $1.02M | $-184.00K | $48.56M | $21.00K | $33.00K | $39.00K | $-342.00K | $27.00K | $10.00K | $134.00K | $290.00K | $352.00K | $1.26M | $31.00K | $214.83M | $-1.24M | $82.69M | $34.43M |
| Net Cash Used Provided by Financing Activities | $-72.00K | $23.00K | $1.02M | $-184.00K | $48.56M | $21.00K | $33.00K | $- | $-171.00K | $27.00K | $10.00K | $134.00K | $290.00K | $352.00K | $1.26M | $31.00K | $214.83M | $-1.08M | $82.69M | $34.43M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $39.00K | $- | $- | $-39.00K | $171.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $13.56M | $-16.86M | $-15.31M | $-49.62M | $84.99M | $-31.26M | $5.85M | $18.66M | $7.62M | $1.89M | $-12.87M | $-41.52M | $7.17M | $-1.40M | $1.76M | $-73.16M | $29.30M | $-2.44M | $93.35M | $30.68M |
| Cash at End of Period | $57.39M | $43.83M | $60.69M | $76.00M | $125.63M | $40.63M | $71.89M | $66.04M | $47.38M | $39.76M | $37.87M | $50.74M | $92.27M | $85.09M | $86.49M | $84.73M | $157.90M | $128.60M | $131.04M | $37.69M |
| Cash at Beginning of Period | $43.83M | $60.69M | $76.00M | $125.63M | $40.63M | $71.89M | $66.04M | $47.38M | $39.76M | $37.87M | $50.74M | $92.27M | $85.09M | $86.49M | $84.73M | $157.90M | $128.60M | $131.04M | $37.69M | $7.01M |
| Operating Cash Flow | $-17.37M | $-16.07M | $-10.92M | $-16.16M | $-19.42M | $-16.73M | $-18.62M | $-26.46M | $-23.84M | $-28.06M | $-16.32M | $-26.28M | $-18.72M | $-12.99M | $-14.34M | $-11.07M | $-14.04M | $-11.35M | $2.19M | $-10.45M |
| Capital Expenditure | $- | $-42.00K | $-17.00K | $- | $-17.00K | $-19.00K | $-296.00K | $-75.00K | $-693.00K | $-750.00K | $-7.68M | $-2.49M | $-1.99M | $-964.00K | $-2.33M | $-2.64M | $-201.00K | $-99.00K | $-319.00K | $-108.00K |
| Free Cash Flow | $-17.37M | $-16.11M | $-10.94M | $-16.16M | $-19.44M | $-16.75M | $-18.91M | $-26.54M | $-24.53M | $-28.81M | $-24.00M | $-28.77M | $-20.71M | $-13.96M | $-16.67M | $-13.71M | $-14.24M | $-11.45M | $1.87M | $-10.56M |
Shattuck Labs Dividends
Explore Shattuck Labs's dividend history, including dividend yield, payout ratio, and historical payments.
Shattuck Labs News
Read the latest news about Shattuck Labs, including recent articles, headlines, and updates.
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present at and participate in one-on-one meetings at the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025.
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
– Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class blocking antibody to DR3, the receptor for TL1A; data demonstrated favorable safety profile, full receptor occupancy, lack of DR3 agonism –
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate toxicology study – – SL-325 receptor occupancy (RO) and pharmacokinetic (PK) profile observed suggestive of extended dosing intervals; IND filing expected in the third quarter of 2025 – AUSTIN, TX & DURHAM, NC, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced positive preclinical data from an IND-enabling GLP toxicology study of SL-325 in non-human primates (NHP). These data were featured in a digital oral presentation on February 20, 2025, during the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025 in Berlin, Germany.
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming oral presentation at the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025 being held in Berlin, Germany from February 19–22, 2025. This presentation will feature results from the IND-enabling toxicology studies of SL-325, a first-in-class DR3 blocking antibody, in non-human primates.
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress
AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming poster presentation at the 2025 Crohn's and Colitis Congress being held in San Francisco, California from February 6–8, 2025.
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
AUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present a corporate update and participate in one-on-one meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California on January 13-16, 2025.
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced a corporate update and highlighted upcoming key milestones anticipated in 2025.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shattuck Labs, Inc. - STTK
NEW YORK CITY, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)---- $STTK #STTK--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. (“Shattuck” or “the Company”) (NASDAQ: STTK). Investors who purchased Shattuck securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/STTK. Investigation Details On October 1, 2024, Shattuck issued a press release announcing the discontinuation of its lead.
Shattuck Labs, Inc. (STTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (NASDAQ:STTK). Investors who purchased Shattuck securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/STTK.
Shattuck Labs, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- STTK
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Shattuck Labs, Inc. ("Shattuck Labs, Inc.") (NASDAQ:STTK) concerning possible violations of federal securities laws. On October 1, 2024, Shattuck issued a press release announcing the discontinuation of its lead experimental therapy SL-172154 following disappointing early-stage data.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / October 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (NASDAQ:STTK). Investors who purchased Shattuck securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/STTK.
Down -64.19% in 4 Weeks, Here's Why Shattuck Labs (STTK) Looks Ripe for a Turnaround
Shattuck Labs (STTK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESSWIRE / October 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (NASDAQ:STTK). Investors who purchased Shattuck securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/STTK.
Investors who lost money on Shattuck Labs, Inc. should contact Levi & Korsinsky about an ongoing investigation - STTK
NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Shattuck Labs, Inc. ("Shattuck Labs, Inc.") (NASDAQ:STTK) concerning possible violations of federal securities laws. On October 1, 2024, Shattuck issued a press release announcing the discontinuation of its lead experimental therapy SL-172154 following disappointing early-stage data.
Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (NASDAQ:STTK). Investors who purchased Shattuck securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/STTK.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for STTK.